NICE: how to switch NHS patients from Remicade to a biosimilar
This article was originally published in Scrip
The National Institute for Health and Care Excellence (NICE) has produced some "practical advice" for NHS staff on how to manage the introduction of the two biosimilar versions of Merck & Co/J&J's Remicade (infliximab) that were launched in the UK in February this year following further patent expiries on the originator.
You may also be interested in...
A new licensing route is to be introduced by the UK MHRA next year for products that meet specific criteria, such as treating life threatening conditions or rare diseases and where there is a significant patient need. At a webinar this week, an MHRA medical assessor looked at the requirements that products will have to meet to enter the new pathway.
Russia seeks WHO endorsement of its Sputnik V vaccine, a UK BioIndustry Association taskforce identifies potential new antibody cocktails, and the European Centre for Disease Prevention and Control considers the best strategies for targeted vaccination programs.
New guidance from the UK covers the recognition of EU approvals, accelerated assessment, rolling reviews, and much else besides.